Table 2 Studies involving the use of palliative external beam radiotherapy for tumor bleeding in advanced gastric cancer
Study | No | Prescribed dose | Symptom response rate | Relation RT dose and treatment outcome | Association between concurrent chemoradiotherapy and treatment outcome | ||
|---|---|---|---|---|---|---|---|
Significant dose (BEDa) | Symptom response | Re-bleeding | |||||
Hashimoto et al. [10] | 19 | 40 Gy/16fx (range,2–50 Gy/1.8–3 Gy per fx) | 68.4% | 50 Gy10 | Yes (P = 0.040) | NR b | NR b |
Asakura et al. [7] | 30 | 30 Gy/10 fx (90% of patients) | 73% | 39 Gy10 | NR b | NR b | Decreased re-bleeding event (60% vs. 17.5%, P = 0.001) |
Lee et al. [17] | 23 | 30 Gy/10fx (range, 30-44Gy/10-22fx) | 91% | NR b | NR b | NR b | NR b, g |
Kim et al. [11] | 20 c | 35 Gy/14 fx c (m/c) | 70% c | 41 Gy10 d | NR d | Yes d (P = 0.05) | A trend towards better OS d (6- month OS 50% vs. 23%, P = 0.08) |
Tey et al. [8] | 103 e | 30 Gy/10fx (m/c) 8-Gy/1fx-40Gy/16fx | 80.6% e | 39 Gy10 e, f | No e (P = 0.78) | No e (P = 0.78) | NR b, g |
Chaw et al. [16] | 44 | 8 Gy/fx (75%) or 20 Gy/5fx (25%) | 50% | 14.4 or 28 Gy10 | No (P = 0.202) | NR b | NR b, g |
Present study | 42 | 39.6 Gy/20fx (range, 14–50.4 Gy/7-28fx) | 69% | 36 Gy10 | Yes (P < 0.001) | No (P = 0.238) | A trend towards better symptom response rate (24.1% vs. 0%, P = 0.079) |